Back to results

Coenzyme Q10 in Huntington's Disease (HD) (2CARE)

Primary Purpose

Huntington's Disease

Status

Terminated

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

coenzyme Q10

placebo

About this trial

This is an interventional treatment trial for Huntington's Disease focused on measuring Huntington's disease, Huntington disease, HD, coenzyme Q10, CoQ

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

To be eligible for enrollment into this study, subjects must meet the following eligibility criteria within 28 days prior to randomization:

Subjects must have clinical features of HD and a confirmed family history of HD, OR a CAG repeat expansion ≥ 36.
TFC > 9.
Must be ambulatory and not require skilled nursing care.
Age ≥ 16 years.
Women must not be able to become pregnant (e.g., post menopausal, surgically sterile or using adequate birth control methods for the duration of the study).
If psychotropic medications are taken (e.g., anxiolytics, hypnotics, benzodiazepines, antidepressants), they must be at a stable dosage for four weeks prior to randomization and should be maintained at a constant dosage throughout the study, as possible. (Note: stable dosing of tetrabenazine is allowable.) Any changes to these medications mandated by clinical conditions will be systematically recorded and the subject will be permitted to remain in the trial.
Able to give informed consent and comply with trial procedures
Able to take oral medication.
May be required to identify an informant or caregiver who will be willing and able to supervise the daily dosing of study medications and to maintain control of study medications in the home.
A designated individual will be identified by the subject to participate in the ongoing consent process should the subject's cognitive capacity to consent become compromised during participation in the study.

Exclusion Criteria:

History or known sensitivity of intolerability to CoQ.
Exposure to any investigational drug within 30 days of the Baseline visit.
Clinical evidence of unstable medical illness in the investigator's judgment.
Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression or suicidal ideation within 90 days of the Baseline visit.
Substance (alcohol or drug) abuse within one year of the Baseline visit.
Women who are pregnant or breastfeeding.
Use of supplemental coenzyme Q10 within 30 days prior to the Baseline visit
Clinically serious abnormalities in the screening laboratory studies (Screening creatinine greater than 2.0, alanine aminotransferase (ALT) or total bilirubin greater than 3 times the upper limit of normal, absolute neutrophil count of ≤1000/ul, platelet concentration of <100,000/ul, hematocrit level of <33 for female or <35 for male, or coagulation tests > 1.5 time upper limit of normal).
Known allergy to FD&C yellow #5 or any other ingredient in the study drug (active and placebo)

Sites / Locations

University of Alabama At Birmingham, Pediatric Neurology Childrens, Harbor Bldg Suite 314, 1600 7Th Avenue South
Mayo Clinic Arizona, 13400 East Shea Boulevard, Csu-Cp21B
WASHINGTON REGIONAL MEDICAL CENTER, 3215 N. North Hills Blvd
University of California Irvine, Department of Neurology, 100 Irvine Hall
University of California Davis, Medical Center Dept of Neurology, Acc Building Suite 3700, 4860 Y Street
Colorado Neurological Institute, Movement Disorders Center, 701 East Hampden Avenue Suite 510
University of Florida Center for Movement Disorders and Neurorestoration, 3450 Hull Road, 4th Floor
UNIVERSITY OF MIAMI, 1150 NW 14th STREET, #401
University of South Florida, College of Medicine Dept of Neurology, 12901 Bruce B Downs Blvd Mdc-55
Emory University, Wesley Woods Center, 1841 Clifton Road NE Room 314
Idaho Elks Rehabilitation Hospital, 600 North Robbins Road
Rush University Medical Center, Department of Neurological Sciences, 1725 West Harrison Suite 755
Indiana University School of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150
University of Iowa Hospital and Clinics, 200 Hawkins Road, Room W263 General Hospital
University of Kansas Medical Center, Department of Neurology, 3599 Rainbow Blvd Mail Stop 2012
Hereditary Neurological Disease Centre (Hndc),3223 N. Webb, Suite 4
University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B
Johns Hopkins University, 600 North Wolfe Street, Meyer 2-181
Boston University School of Medicine, Department of Neurology, 715 Albany Street C329
Massachusetts General Hospital, 149 13Th Street Suite 2241
University of Michigan, 1500 E Medical Center Drive, B1 H202 Nuclear Medicine
Struthers Parkinson'S Center, 6701 Country Club Drive
Washington University School of Medicine, Box 8111, 660 South Euclid
University of Las Vegas School of Medicine, 1707 W. Charleston Blvd, Suite 220
Cooper University Hospital
Nj Neuroscience Institute, Jfk Medical Center, 65 James Street
Albany Medical College, Parkinson'S Disease & Movement Disorders Ctr
North Shore-Lij Health System, 350 Community Drive Room 110, Research Institute
Columbia University, Sergievsky Center P&S Box 16, 630 West 168Th Street
University of Rochester, Department of Neurology, 919 Westfall Road Building C Suite 220
Duke University, 932 Morreene Road #213
Wake Forest University, Baptist Med Center, Department of Neurology, Medical Center Boulevard
University of Cincinnati/Cincinnati Children'S Hospital, 222 Piedmont Avenue, Suite 3200
OHIO STATE UNIVERSITY , 2006 Kenny Road
ST. LUKE'S HOSPITAL, 240 Centronia Road
University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street
University of Pittsburgh Kaufmann Medical Building, 3471 Fifth Avunue, Suite 811
BUTLER HOSPTIAL MOVEMENT DISORDER PROGRAM, 345 Blackstone Boulevard
The University of Tennesee Health Science Cen, 855 Monroe Avenue, Department of Neurology, Room 415 Link Bldg
UN oF TEXAS SOUTHWESTERN MED CENTER DALLAS, 5323 HARRY HINES BOULEVARD H1.108
Baylor College of Medicine, 6550 Fannin Suite 1801
Westmead Hospital, Department of Neurology Level 1, Po Box 533
University of Calgary, Heritage Medical Research Clinic, Trw Bldg 5 Floor, 3280 Hospital Dri. NW
University of Alberta, Glenrose Rehab Hosp, Movement Disorder Clinic , Rm 0601 Gleneast 10230 - 111 Avenue
Department of Medical Genetics, Ubc Hospital, Room S179-2211 Westbrook Mall
London Health Sciences Centre, University Hospital, 339 Windermere Road
Centre For Movement Disorders, 2780 Bur Oak Avenue
NORTH YORK GENERAL HOSPITAL (2), 4001 Leslie Street
North York General Hospital, 4001 Leslie Street

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

A - coenzyme Q10 2400 mg/day

B - Placebo

Arm Description

Randomized to active treatment (coenzyme Q10 2400 mg/day)

Randomized to placebo

Outcomes

Primary Outcome Measures

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).

Secondary Outcome Measures

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best).

Change in Functional Checklist Score From Baseline to Month 60

The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each "yes" reply and a score of 0 is given for each "no" reply (scale range is 0-25). Higher scores indicate better functioning.

Change in Independence Scale Score From Baseline to Month 60

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning.

Change in Total Motor Score From Baseline to Month 60

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124.

Change in Behavioral Frequency Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment.

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment.

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning.

Change in Verbal Fluency Test From Baseline to Month 60

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials.

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed.

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed.

Change in Stroop Interference Test - Interference From Baseline to Month 60

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability.

Time to a Two-Point Decline in TFC Score or Death

Time to a Three-Point Decline in TFC Score or Death

Number Completing Study at Assigned Dosage Level

Full Information

NCT ID

NCT00608881

First Posted

February 4, 2008

Last Updated

February 29, 2016

Sponsor

Massachusetts General Hospital

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS), University of Rochester

1. Study Identification

Unique Protocol Identification Number

NCT00608881

Brief Title

Coenzyme Q10 in Huntington's Disease (HD)

Acronym

2CARE

Official Title

Coenzyme Q10 in Huntington's Disease (HD)

Study Type

Interventional

2. Study Status

Record Verification Date

February 2016

Overall Recruitment Status

Terminated

Why Stopped

Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.

Study Start Date

March 2008 (undefined)

Primary Completion Date

November 2014 (Actual)

Study Completion Date

May 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

Massachusetts General Hospital

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS), University of Rochester

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its effects on people with Huntington's disease.

Detailed Description

Huntington's disease (HD) is a slowly progressive disorder that devastates the lives of those affected and their families. There are no treatments that slow the progression of HD, only mildly effective symptomatic therapies are available. The purpose of this trial is to find out if coenzyme Q10 (CoQ) is effective in slowing the worsening symptoms of HD. In this study, researchers also will learn about the safety and acceptability of long-term CoQ use by determining its effects on people with HD. Participants in this trial will be randomly chosen to one of two groups. Group 1 will receive CoQ (2400 mg/day), and group 2 will receive a placebo (an inactive substance). Researchers will compare the change in total functional capacity (TFC)-a measure of functional disability-in the two groups. The TFC is a valid and reliable measure of disease progression and is particularly responsive to change in the early and mid-stages of HD. Researchers will also compare the changes in other components of the Unified Huntington's Disease Rating Scale '99 (UHDRS) including: the total motor score, total behavioral frequency score, total behavior frequency X severity score, verbal fluency test, symbol digit modalities test, Stroop, interference test, functional checklist, and independence scale scores. The groups will also be compared with respect to tolerability, adverse events, vital signs, and laboratory test results as measures of safety.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Huntington's Disease

Keywords

Huntington's disease, Huntington disease, HD, coenzyme Q10, CoQ

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigator

Allocation

Randomized

Enrollment

609 (Actual)

8. Arms, Groups, and Interventions

Arm Title

A - coenzyme Q10 2400 mg/day

Arm Type

Active Comparator

Arm Description

Randomized to active treatment (coenzyme Q10 2400 mg/day)

Arm Title

B - Placebo

Arm Type

Placebo Comparator

Arm Description

Randomized to placebo

Intervention Type

Drug

Intervention Name(s)

coenzyme Q10

Other Intervention Name(s)

CoQ

Intervention Description

4 - 300 mg CoQ chewable wafers taken orally twice a day

Intervention Type

Other

Intervention Name(s)

placebo

Intervention Description

an inactive substance

Primary Outcome Measure Information:

Title

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

Description

Time Frame

5 years

Secondary Outcome Measure Information:

Title

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

Description

Time Frame

Baseline and Month 60

Title

Change in Functional Checklist Score From Baseline to Month 60

Description

Time Frame

Baseline and Month 60

Title

Change in Independence Scale Score From Baseline to Month 60

Description

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning.

Time Frame

Baseline and Month 60

Title

Change in Total Motor Score From Baseline to Month 60

Description

Time Frame

Baseline and Month 60

Title

Change in Behavioral Frequency Score From Baseline to Month 60

Description

Time Frame

Baseline and Month 60

Title

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

Description

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment.

Time Frame

Baseline and Month 60

Title

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

Description

Time Frame

Baseline and Month 60

Title

Change in Verbal Fluency Test From Baseline to Month 60

Description

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials.

Time Frame

Baseline and Month 60

Title

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Description

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed.

Time Frame

Baseline and Month 60

Title

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Description

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed.

Time Frame

Baseline and Month 60

Title

Change in Stroop Interference Test - Interference From Baseline to Month 60

Description

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability.

Time Frame

Baseline and Month 60

Title

Time to a Two-Point Decline in TFC Score or Death

Description

Time Frame

5 years

Title

Time to a Three-Point Decline in TFC Score or Death

Description

Time Frame

5 years

Title

Number Completing Study at Assigned Dosage Level

Time Frame

5 years

10. Eligibility

Sex

All

Minimum Age & Unit of Time

16 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: To be eligible for enrollment into this study, subjects must meet the following eligibility criteria within 28 days prior to randomization: Subjects must have clinical features of HD and a confirmed family history of HD, OR a CAG repeat expansion ≥ 36. TFC > 9. Must be ambulatory and not require skilled nursing care. Age ≥ 16 years. Women must not be able to become pregnant (e.g., post menopausal, surgically sterile or using adequate birth control methods for the duration of the study). If psychotropic medications are taken (e.g., anxiolytics, hypnotics, benzodiazepines, antidepressants), they must be at a stable dosage for four weeks prior to randomization and should be maintained at a constant dosage throughout the study, as possible. (Note: stable dosing of tetrabenazine is allowable.) Any changes to these medications mandated by clinical conditions will be systematically recorded and the subject will be permitted to remain in the trial. Able to give informed consent and comply with trial procedures Able to take oral medication. May be required to identify an informant or caregiver who will be willing and able to supervise the daily dosing of study medications and to maintain control of study medications in the home. A designated individual will be identified by the subject to participate in the ongoing consent process should the subject's cognitive capacity to consent become compromised during participation in the study. Exclusion Criteria: History or known sensitivity of intolerability to CoQ. Exposure to any investigational drug within 30 days of the Baseline visit. Clinical evidence of unstable medical illness in the investigator's judgment. Unstable psychiatric illness defined as psychosis (hallucinations or delusions), untreated major depression or suicidal ideation within 90 days of the Baseline visit. Substance (alcohol or drug) abuse within one year of the Baseline visit. Women who are pregnant or breastfeeding. Use of supplemental coenzyme Q10 within 30 days prior to the Baseline visit Clinically serious abnormalities in the screening laboratory studies (Screening creatinine greater than 2.0, alanine aminotransferase (ALT) or total bilirubin greater than 3 times the upper limit of normal, absolute neutrophil count of ≤1000/ul, platelet concentration of <100,000/ul, hematocrit level of <33 for female or <35 for male, or coagulation tests > 1.5 time upper limit of normal). Known allergy to FD&C yellow #5 or any other ingredient in the study drug (active and placebo)

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Merit Cudkowicz, MD MSc

Organizational Affiliation

Massachusetts General Hospital

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Michael McDermott, PhD

Organizational Affiliation

University of Rochester, Biostatistics

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Karl Kieburtz, MD MPH

Organizational Affiliation

Director, Clinical Trials Coordination Center, University of Rochester

Official's Role

Principal Investigator

Facility Information:

Facility Name

University of Alabama At Birmingham, Pediatric Neurology Childrens, Harbor Bldg Suite 314, 1600 7Th Avenue South

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35233-1711

Country

United States

Facility Name

Mayo Clinic Arizona, 13400 East Shea Boulevard, Csu-Cp21B

City

Scottsdale

State/Province

Arizona

ZIP/Postal Code

85259

Country

United States

Facility Name

WASHINGTON REGIONAL MEDICAL CENTER, 3215 N. North Hills Blvd

City

Fayetteville

State/Province

Arkansas

ZIP/Postal Code

72703

Country

United States

Facility Name

University of California Irvine, Department of Neurology, 100 Irvine Hall

City

Irvine

State/Province

California

ZIP/Postal Code

92697-4275

Country

United States

Facility Name

University of California Davis, Medical Center Dept of Neurology, Acc Building Suite 3700, 4860 Y Street

City

Sacramento

State/Province

California

ZIP/Postal Code

95817

Country

United States

Facility Name

Colorado Neurological Institute, Movement Disorders Center, 701 East Hampden Avenue Suite 510

City

Littleton

State/Province

Colorado

ZIP/Postal Code

80120

Country

United States

Facility Name

University of Florida Center for Movement Disorders and Neurorestoration, 3450 Hull Road, 4th Floor

City

Gainesville

State/Province

Florida

ZIP/Postal Code

32607

Country

United States

Facility Name

UNIVERSITY OF MIAMI, 1150 NW 14th STREET, #401

City

Miami

State/Province

Florida

ZIP/Postal Code

33136

Country

United States

Facility Name

University of South Florida, College of Medicine Dept of Neurology, 12901 Bruce B Downs Blvd Mdc-55

City

Tampa

State/Province

Florida

ZIP/Postal Code

33612

Country

United States

Facility Name

Emory University, Wesley Woods Center, 1841 Clifton Road NE Room 314

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30329

Country

United States

Facility Name

Idaho Elks Rehabilitation Hospital, 600 North Robbins Road

City

Boise

State/Province

Idaho

ZIP/Postal Code

83702

Country

United States

Facility Name

Rush University Medical Center, Department of Neurological Sciences, 1725 West Harrison Suite 755

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60612

Country

United States

Facility Name

Indiana University School of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150

City

Indianapolis

State/Province

Indiana

ZIP/Postal Code

46202

Country

United States

Facility Name

University of Iowa Hospital and Clinics, 200 Hawkins Road, Room W263 General Hospital

City

Iowa City

State/Province

Iowa

ZIP/Postal Code

52242-1000

Country

United States

Facility Name

University of Kansas Medical Center, Department of Neurology, 3599 Rainbow Blvd Mail Stop 2012

City

Kansas City

State/Province

Kansas

ZIP/Postal Code

66160-7314

Country

United States

Facility Name

Hereditary Neurological Disease Centre (Hndc),3223 N. Webb, Suite 4

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67226

Country

United States

Facility Name

University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21201

Country

United States

Facility Name

Johns Hopkins University, 600 North Wolfe Street, Meyer 2-181

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21287

Country

United States

Facility Name

Boston University School of Medicine, Department of Neurology, 715 Albany Street C329

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02118

Country

United States

Facility Name

Massachusetts General Hospital, 149 13Th Street Suite 2241

City

Charlestown

State/Province

Massachusetts

ZIP/Postal Code

02129

Country

United States

Facility Name

University of Michigan, 1500 E Medical Center Drive, B1 H202 Nuclear Medicine

City

Ann Arbor

State/Province

Michigan

ZIP/Postal Code

48109-0028

Country

United States

Facility Name

Struthers Parkinson'S Center, 6701 Country Club Drive

City

Golden Valley

State/Province

Minnesota

ZIP/Postal Code

55427

Country

United States

Facility Name

Washington University School of Medicine, Box 8111, 660 South Euclid

City

St Louis

State/Province

Missouri

ZIP/Postal Code

63110

Country

United States

Facility Name

University of Las Vegas School of Medicine, 1707 W. Charleston Blvd, Suite 220

City

Las Vegas

State/Province

Nevada

ZIP/Postal Code

89102

Country

United States

Facility Name

Cooper University Hospital

City

Camden

State/Province

New Jersey

ZIP/Postal Code

08103

Country

United States

Facility Name

Nj Neuroscience Institute, Jfk Medical Center, 65 James Street

City

Edison

State/Province

New Jersey

ZIP/Postal Code

08818

Country

United States

Facility Name

Albany Medical College, Parkinson'S Disease & Movement Disorders Ctr

City

Albany

State/Province

New York

ZIP/Postal Code

12208

Country

United States

Facility Name

North Shore-Lij Health System, 350 Community Drive Room 110, Research Institute

City

Manhasset

State/Province

New York

ZIP/Postal Code

11030

Country

United States

Facility Name

Columbia University, Sergievsky Center P&S Box 16, 630 West 168Th Street

City

New York

State/Province

New York

ZIP/Postal Code

10032

Country

United States

Facility Name

University of Rochester, Department of Neurology, 919 Westfall Road Building C Suite 220

City

Rochester

State/Province

New York

ZIP/Postal Code

14618

Country

United States

Facility Name

Duke University, 932 Morreene Road #213

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27705

Country

United States

Facility Name

Wake Forest University, Baptist Med Center, Department of Neurology, Medical Center Boulevard

City

Winston Salem

State/Province

North Carolina

ZIP/Postal Code

27157

Country

United States

Facility Name

University of Cincinnati/Cincinnati Children'S Hospital, 222 Piedmont Avenue, Suite 3200

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45219

Country

United States

Facility Name

OHIO STATE UNIVERSITY , 2006 Kenny Road

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43212

Country

United States

Facility Name

ST. LUKE'S HOSPITAL, 240 Centronia Road

City

Allentown

State/Province

Pennsylvania

ZIP/Postal Code

18104

Country

United States

Facility Name

University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107

Country

United States

Facility Name

University of Pittsburgh Kaufmann Medical Building, 3471 Fifth Avunue, Suite 811

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15213

Country

United States

Facility Name

BUTLER HOSPTIAL MOVEMENT DISORDER PROGRAM, 345 Blackstone Boulevard

City

Providence

State/Province

Rhode Island

ZIP/Postal Code

02906

Country

United States

Facility Name

The University of Tennesee Health Science Cen, 855 Monroe Avenue, Department of Neurology, Room 415 Link Bldg

City

Memphis

State/Province

Tennessee

ZIP/Postal Code

38163

Country

United States

Facility Name

UN oF TEXAS SOUTHWESTERN MED CENTER DALLAS, 5323 HARRY HINES BOULEVARD H1.108

City

Dallas

State/Province

Texas

ZIP/Postal Code

75390-9016

Country

United States

Facility Name

Baylor College of Medicine, 6550 Fannin Suite 1801

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Facility Name

Westmead Hospital, Department of Neurology Level 1, Po Box 533

City

Wentworthville

State/Province

New South Wales

ZIP/Postal Code

2145

Country

Australia

Facility Name

University of Calgary, Heritage Medical Research Clinic, Trw Bldg 5 Floor, 3280 Hospital Dri. NW

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T2N 4Z6

Country

Canada

Facility Name

University of Alberta, Glenrose Rehab Hosp, Movement Disorder Clinic , Rm 0601 Gleneast 10230 - 111 Avenue

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T5G 0B7

Country

Canada

Facility Name

Department of Medical Genetics, Ubc Hospital, Room S179-2211 Westbrook Mall

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V6T 2B5

Country

Canada

Facility Name

London Health Sciences Centre, University Hospital, 339 Windermere Road

City

London

State/Province

Ontario

ZIP/Postal Code

N6A 5A5

Country

Canada

Facility Name

Centre For Movement Disorders, 2780 Bur Oak Avenue

City

Markham

State/Province

Ontario

ZIP/Postal Code

L4A 1G8

Country

Canada

Facility Name

NORTH YORK GENERAL HOSPITAL (2), 4001 Leslie Street

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M2K 1E1

Country

Canada

Facility Name

North York General Hospital, 4001 Leslie Street

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M2R 1N5

Country

Canada

12. IPD Sharing Statement

Citations:

Citation

Kowall N, Ferrante R, Martin J. Patterns of cell loss in Huntington's disease. Trends in Neurosciences 1987;10:24-29.

Results Reference

background

Citation

Riley D, Lang A. Movement Disorders. In: Bradley W, Daroff R, Fenichel G, eds. Neurology in Clinical Practice. The Neurological Disorders. Boston: Butterworth-Heinemann, 1991: 1563-1601.

Results Reference

background

PubMed Identifier

2973230

Citation

Adams P, Falek A, Arnold J. Huntington disease in Georgia: age at onset. Am J Hum Genet. 1988 Nov;43(5):695-704.

Results Reference

background

PubMed Identifier

6233902

Citation

Conneally PM. Huntington disease: genetics and epidemiology. Am J Hum Genet. 1984 May;36(3):506-26.

Results Reference

background

PubMed Identifier

1535611

Citation

Harper PS. The epidemiology of Huntington's disease. Hum Genet. 1992 Jun;89(4):365-76. doi: 10.1007/BF00194305.

Results Reference

background

PubMed Identifier

7952243

Citation

Tanner CM, Goldman SM. Epidemiology of movement disorders. Curr Opin Neurol. 1994 Aug;7(4):340-5. doi: 10.1097/00019052-199408000-00011. No abstract available.

Results Reference

background

PubMed Identifier

2935747

Citation

Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 1986 Feb;36(2):244-9. doi: 10.1212/wnl.36.2.244.

Results Reference

background

Citation

Bruyn G. Huntington's chorea: Historical clinical and laboratory synopsis. In: Vinken P, Bruyn G, eds. Handbook of Clinical Neurology. Amsterdam, 1968: 298-378.

Results Reference

background

PubMed Identifier

6225033

Citation

Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA. Abnormal ocular motor control in Huntington's disease. Neurology. 1983 Oct;33(10):1268-75. doi: 10.1212/wnl.33.10.1268.

Results Reference

background

PubMed Identifier

153122

Citation

Caine ED, Hunt RD, Weingartner H, Ebert MH. Huntington's dementia. Clinical and neuropsychological features. Arch Gen Psychiatry. 1978 Mar;35(3):377-84. doi: 10.1001/archpsyc.1978.01770270127013.

Results Reference

background

PubMed Identifier

2524678

Citation

Bamford KA, Caine ED, Kido DK, Plassche WM, Shoulson I. Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology. 1989 Jun;39(6):796-801. doi: 10.1212/wnl.39.6.796.

Results Reference

background

PubMed Identifier

1479606

Citation

Sorensen SA, Fenger K. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet. 1992 Dec;29(12):911-4. doi: 10.1136/jmg.29.12.911.

Results Reference

background

PubMed Identifier

4244787

Citation

Oliver JE. Huntington's chorea in Northamptonshire. Br J Psychiatry. 1970 Mar;116(532):241-53. doi: 10.1192/bjp.116.532.241. No abstract available.

Results Reference

background

Citation

Greenamyre J, Shoulson I. Huntington's Disease. In: Calne D, ed. Neurodegenerative Diseases. Philadelphia: WB Saunders, 1994: 685-704.

Results Reference

background

PubMed Identifier

154626

Citation

Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979 Jan;29(1):1-3. doi: 10.1212/wnl.29.1.1. No abstract available.

Results Reference

background

PubMed Identifier

7753064

Citation

Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I. Functional decline in Huntington's disease. Mov Disord. 1995 Mar;10(2):211-4. doi: 10.1002/mds.870100213.

Results Reference

background

PubMed Identifier

1832854

Citation

Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED. Factors associated with slow progression in Huntington's disease. Arch Neurol. 1991 Aug;48(8):800-4. doi: 10.1001/archneur.1991.00530200036015.

Results Reference

background

PubMed Identifier

2139171

Citation

Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, Ramos-Arroyo M, Gomez F, Penchaszadeh G, Alvir J, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord. 1990;5(2):93-9. doi: 10.1002/mds.870050202.

Results Reference

background

PubMed Identifier

2945510

Citation

Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986 Sep;20(3):296-303. doi: 10.1002/ana.410200305.

Results Reference

background

Citation

Kido D, Shoulson I, Manzione J, Harnish P. Measurement of caudate nucleus and putamen atrophy in patients with Huntington's disease. Neuroradiology 1991;33:604-606.

Results Reference

background

PubMed Identifier

2534934

Citation

Mazziotta JC. Huntington's disease: studies with structural imaging techniques and positron emission tomography. Semin Neurol. 1989 Dec;9(4):360-9. doi: 10.1055/s-2008-1041346. No abstract available.

Results Reference

background

PubMed Identifier

15100720

Citation

Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci. 2004 May;5(5):373-84. doi: 10.1038/nrn1386. No abstract available.

Results Reference

background

PubMed Identifier

8458085

Citation

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993 Mar 26;72(6):971-83. doi: 10.1016/0092-8674(93)90585-e.

Results Reference

background

PubMed Identifier

10632104

Citation

Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000 Jan;47(1):80-6. doi: 10.1002/1531-8249(200001)47:13.3.co;2-b.

Results Reference

background

PubMed Identifier

10941183

Citation

Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000 Sep;23(9):387-92. doi: 10.1016/s0166-2236(00)01609-x.

Results Reference

background

PubMed Identifier

10353249

Citation

Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 1999 May 20;399(6733):263-7. doi: 10.1038/20446.

Results Reference

background

PubMed Identifier

10888929

Citation

Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. doi: 10.1038/77528.

Results Reference

background

PubMed Identifier

7682343

Citation

Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993 Apr;16(4):125-31. doi: 10.1016/0166-2236(93)90117-5.

Results Reference

background

PubMed Identifier

9535906

Citation

Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, Rowland KJ, Zhang T, Rasper D, Roy S, Thornberry N, Pinsky L, Kakizuka A, Ross CA, Nicholson DW, Bredesen DE, Hayden MR. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998 Apr 10;273(15):9158-67. doi: 10.1074/jbc.273.15.9158.

Results Reference

background

PubMed Identifier

7624378

Citation

Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7105-9. doi: 10.1073/pnas.92.15.7105.

Results Reference

background

PubMed Identifier

8602759

Citation

Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996 Mar;39(3):385-9. doi: 10.1002/ana.410390317.

Results Reference

background

PubMed Identifier

9029064

Citation

Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol. 1997 Feb;41(2):160-5. doi: 10.1002/ana.410410206.

Results Reference

background

PubMed Identifier

10502825

Citation

Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenamyre JT, Snyder SH, Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999 Oct;5(10):1194-8. doi: 10.1038/13518.

Results Reference

background

PubMed Identifier

8255479

Citation

Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993 Dec;43(12):2689-95. doi: 10.1212/wnl.43.12.2689.

Results Reference

background

PubMed Identifier

10894218

Citation

Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000 Jul;48(1):72-6.

Results Reference

background

PubMed Identifier

12089530

Citation

Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002 Aug;5(8):731-6. doi: 10.1038/nn884.

Results Reference

background

PubMed Identifier

12588797

Citation

Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet. 2003 Mar 1;12(5):497-508. doi: 10.1093/hmg/ddg046.

Results Reference

background

PubMed Identifier

9153527

Citation

Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997 May;41(5):646-53. doi: 10.1002/ana.410410514.

Results Reference

background

PubMed Identifier

10844007

Citation

Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000 Jun 15;20(12):4389-97. doi: 10.1523/JNEUROSCI.20-12-04389.2000.

Results Reference

background

PubMed Identifier

11880489

Citation

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002 Mar 1;22(5):1592-9. doi: 10.1523/JNEUROSCI.22-05-01592.2002.

Results Reference

background

PubMed Identifier

12787055

Citation

Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003 Jun;85(6):1359-67. doi: 10.1046/j.1471-4159.2003.01706.x.

Results Reference

background

PubMed Identifier

11716985

Citation

Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001 Nov 27;315(3):149-53. doi: 10.1016/s0304-3940(01)02326-6.

Results Reference

background

PubMed Identifier

9671775

Citation

Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7. doi: 10.1073/pnas.95.15.8892.

Results Reference

background

PubMed Identifier

7998775

Citation

Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol. 1994 Dec;36(6):882-8. doi: 10.1002/ana.410360613.

Results Reference

background

PubMed Identifier

10192685

Citation

Pepping J. Coenzyme Q10. Am J Health Syst Pharm. 1999 Mar 15;56(6):519-21. doi: 10.1093/ajhp/56.6.519. No abstract available.

Results Reference

background

PubMed Identifier

11294920

Citation

Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, Weissman BM, Tsao CY, Mendell JR, Shanske S, De Vivo DC, Hirano M, DiMauro S. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001 Apr 10;56(7):849-55. doi: 10.1212/wnl.56.7.849.

Results Reference

background

PubMed Identifier

7599208

Citation

Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204. doi: 10.1016/0925-4439(95)00028-3.

Results Reference

background

Citation

Yamagami T, Okishio T, Toyama S, Kishi T. Correlation of serum coenzyme Q10 level and leukocute complex II activity in nformal and cardiovascular patients. In: Folkers K, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q: Elsevier Science Publishers, 1981: 79-89.

Results Reference

background

PubMed Identifier

2299344

Citation

Soderberg M, Edlund C, Kristensson K, Dallner G. Lipid compositions of different regions of the human brain during aging. J Neurochem. 1990 Feb;54(2):415-23. doi: 10.1111/j.1471-4159.1990.tb01889.x.

Results Reference

background

PubMed Identifier

8526244

Citation

Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, Folstein SE. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry. 1995 Dec;152(12):1771-5. doi: 10.1176/ajp.152.12.1771.

Results Reference

background

PubMed Identifier

8866496

Citation

Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, Folstein MF, Brandt J, Ross CA, Folstein SE. A controlled trial of idebenone in Huntington's disease. Mov Disord. 1996 Sep;11(5):549-54. doi: 10.1002/mds.870110510.

Results Reference

background

PubMed Identifier

10496259

Citation

Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, Mezei M, Hardy MA, Snow B, Martin W, Hayden MR. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology. 1999 Sep 22;53(5):1000-11. doi: 10.1212/wnl.53.5.1000.

Results Reference

background

PubMed Identifier

16043801

Citation

Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005 Jul 26;65(2):286-92. doi: 10.1212/01.wnl.0000169025.09670.6d.

Results Reference

background

Citation

Dubois B, Brand M, Garcia de Yebenes J, et al. European-Huntington's-disease-Initiative (EHDI)-Trial: Objectives, design, and description of the study population at the end of inclusion. Mov Dis 2002;17:S319.

Results Reference

background

Citation

Bogentoft C, Edelund P, Olsson B, Widlund L, Westensen K. Biopharmaceutical aspects of intraveneous and oral administration of coenzyme Q10. In: Folkers K, Littarru G, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q.: Elsevier Science Publishers, 1991: 215-224.

Results Reference

background

Citation

Lucker P, Wetselsberg N, Hennings G, Rehn D. Pharmacokinetics of coenzyme ubidecarenone in healthy volunteers. In: Folkers K, Littarru G, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q: Elsevier Science Publishers, 1984: 143-151.

Results Reference

background

PubMed Identifier

1637852

Citation

Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992 Jun 26;1126(3):247-54. doi: 10.1016/0005-2760(92)90237-p.

Results Reference

background

Citation

Micromedex. Ubidecarenone drug monograph. Engelwood 1995 May; Update 1998 Mar.

Results Reference

background

PubMed Identifier

7876919

Citation

Zhang Y, Aberg F, Appelkvist EL, Dallner G, Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr. 1995 Mar;125(3):446-53. doi: 10.1093/jn/125.3.446.

Results Reference

background

Citation

Weber C. Dietary intake and absorption of coenzyme Q. In: Kagan V, Quinn P, eds. Coenzyme Q: Molecular Mechanisms in Health and Disease. Boca Raton: CRC Press, 2001:209-215.

Results Reference

background

PubMed Identifier

15210526

Citation

Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004 Jun;61(6):889-92. doi: 10.1001/archneur.61.6.889.

Results Reference

background

Citation

Saito Y, Kubo H, Bujo H, Yamamoto Y. The changes in plasma coenzyme Q10 level during the statin therapy for hypercholesterolemic patients. In: Second Conference of the International Coenzyme Q10 Association.; 2000, 2000: 59.

Results Reference

background

PubMed Identifier

8877024

Citation

De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A, Jacotot B, Gherardi R. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996 Sep;42(3):333-7. doi: 10.1046/j.1365-2125.1996.04178.x.

Results Reference

background

PubMed Identifier

8254097

Citation

Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 1993 Nov;46(11):1055-7. doi: 10.1136/jcp.46.11.1055.

Results Reference

background

PubMed Identifier

8623738

Citation

Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996 Apr 15;77(10):851-4. doi: 10.1016/S0002-9149(97)89180-1.

Results Reference

background

PubMed Identifier

15304592

Citation

Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology. 2004 Aug 10;63(3):547-9. doi: 10.1212/01.wnl.0000133403.30559.ff.

Results Reference

background

PubMed Identifier

7752828

Citation

Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med. 1994;15 Suppl:s165-75. doi: 10.1016/0098-2997(94)90026-4.

Results Reference

background

PubMed Identifier

2928337

Citation

Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2379-82. doi: 10.1073/pnas.86.7.2379.

Results Reference

background

PubMed Identifier

11502923

Citation

Di Giovanni S, Mirabella M, Spinazzola A, Crociani P, Silvestri G, Broccolini A, Tonali P, Di Mauro S, Servidei S. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001 Aug 14;57(3):515-8. doi: 10.1212/wnl.57.3.515.

Results Reference

background

PubMed Identifier

11357949

Citation

Lodi R, Hart PE, Rajagopalan B, Taylor DJ, Crilley JG, Bradley JL, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol. 2001 May;49(5):590-6.

Results Reference

background

PubMed Identifier

12374491

Citation

Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50. doi: 10.1001/archneur.59.10.1541.

Results Reference

background

PubMed Identifier

15246848

Citation

Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004 Aug;188(2):491-4. doi: 10.1016/j.expneurol.2004.05.003.

Results Reference

background

PubMed Identifier

2202752

Citation

Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990 Jul;30(7):596-608. doi: 10.1002/j.1552-4604.1990.tb01862.x.

Results Reference

background

PubMed Identifier

35747889

Citation

McGarry A, Auinger P, Kieburtz KD, Bredlau AL, Hersch SM, Rosas HD. Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease. Neurol Clin Pract. 2022 Apr;12(2):131-138. doi: 10.1212/CPJ.0000000000001161.

Results Reference

derived

PubMed Identifier

30850442

Citation

McGarry A, McDermott MP, Kieburtz K, Fung WLA, McCusker E, Peng J, de Blieck EA, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators. Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology. 2019 Apr 2;92(14):e1643-e1651. doi: 10.1212/WNL.0000000000007244. Epub 2019 Mar 8.

Results Reference

derived

PubMed Identifier

27913695

Citation

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

Results Reference

derived

Learn more about this trial

Coenzyme Q10 in Huntington's Disease (HD)

We'll reach out to this number within 24 hrs